NDAORALTABLETPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
VERZENIO (abemaciclib) by Eli Lilly and Company is kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERZENIO (abemaciclib) is an oral small-molecule CDK4/6 kinase inhibitor approved in 2017 for hormone receptor-positive, HER2-negative breast cancer. It works by blocking cell-cycle progression in cancer cells, slowing tumor growth. The drug is administered as an oral tablet and represents a foundational therapy in the kinase inhibitor class.
$757MPart D
PeakStable
5.3 years to LOEProduct is at peak lifecycle with $757M in Part D spending; expect stable team size focused on lifecycle management and market defense.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Started Oct 2025
285 enrolled
Breast Cancer
Abemaciclib in Newly Diagnosed Meningioma Patients
Started Mar 2025
72 enrolled
Meningioma
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Started Mar 2025
191 enrolled
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Started Mar 2025
18 enrolled
Retroperitoneal SarcomaLiposarcomaDedifferentiated Liposarcoma
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Started Feb 2025
43 enrolled
Metastatic Renal Cell CarcinomaTranslocation Renal Cell Carcinoma
Worked on VERZENIO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.